8-K: Oncocyte Reports Promising 2024 Results, Eyes 2025 Catalysts with Transplant Test Kit

Oncocyte Corp. announces its Q4 2024 and full-year results, highlighting progress in transplant diagnostics and setting the stage for key milestones in 2025.

Summary

• Oncocyte Corp. reported Q4 2024 revenue of $1.5 million and full-year revenue of $1.9 million, primarily from pharma services.
• The company launched its GraftAssure RUO assay in July 2024 and signed a strategic partnership with Bio-Rad Laboratories.
• Oncocyte is focused on developing a regulated organ transplant rejection monitoring test kit, expected to generate significant revenue in the coming years.
• The company anticipates submitting to the FDA by the end of 2025 and receiving FDA authorization in 2026.
• They raised $57 million in equity from January 2023 to March 2025 to fully fund the transplant assay program.
• Medicare claims expansion was achieved for transplant rejection monitoring in January 2025.
• The company expects to announce progress on its multi-center clinical trial, commercial expansion of GraftAssure, and favorable data in 2025.
• Oncocyte's Q4 2024 loss from continuing operations was $33.5 million, or $1.93 per share.
• The company had approximately $10.3 million in cash, cash equivalents, and restricted cash at the end of Q4 2024, excluding the $29.1 million from the February 2025 financing.
• The company expects localized, real-time monitoring to become the standard of care by 2028.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook, highlighting progress in transplant diagnostics, strategic partnerships, and funding. While acknowledging losses and impairment charges, the focus remains on future growth and market leadership.

Positives

• Successful launch of GraftAssure RUO assay in July 2024.
• Strategic partnership and investment from Bio-Rad Laboratories.
• Medicare claims expansion for transplant rejection monitoring.
• Fully funded clinical assay development with $57 million in equity raises.
• Productive first meeting with the FDA, clarifying the de novo pathway for kitted tests.
• Strengthened team with the addition of Andrea James as CFO and Dr. Paul Billings as Consulting Chief Medical Officer.
• The company expects to announce progress on its multi-center clinical trial, commercial expansion of GraftAssure, and favorable data in 2025.
• The company expects to have at least 20 transplant centers signed up for its assay by the end of 2025.

Negatives

• Q4 2024 loss from continuing operations was $33.5 million, or $1.93 per share.
• The company recorded a $41.9 million intangible asset impairment charge in Q4 2024 related to oncology assets.
• The company is considered pre-revenue relative to its strategic objective of commercializing its transplant tests.

Risks

• The company's success depends on obtaining regulatory approvals for its kitted transplant assay.
• Clinical trial results must demonstrate non-inferiority to existing commercial rejection biomarkers.
• The company needs to secure payer support for its assay to drive adoption.
• The company's ability to access capital in the future is crucial for continued development and commercialization.
• The company faces risks inherent in the development and/or commercialization of diagnostic tests or products.

Future Outlook

Oncocyte anticipates a series of catalysts in 2025, including progress on its clinical trial, commercial expansion of GraftAssure, and favorable data. The company is targeting FDA submission by the end of 2025 and authorization in 2026. By 2028, they expect localized, real-time monitoring to become the standard of care.

Management Comments

• Our dynamic team is making swift progress toward delivering a regulated organ transplant rejection monitoring test kit to the market next year.
• We are proud of our ability to stay nimble and move quickly relative to our industry.
• We believe that our market opportunity is promising, and that we must continue to focus and execute.
• The enthusiasm we have seen from transplant centers, patient advocates, and industry partners reinforces our belief that we are building something transformative.

Industry Context

Oncocyte is positioning itself to capitalize on the shift towards decentralized, in-lab diagnostics in the transplant rejection monitoring market. The company's kitted test aims to provide faster, more affordable, and localized testing solutions compared to centralized labs. This aligns with the broader industry trend of democratizing access to molecular diagnostics.

Comparison to Industry Standards

• The document mentions Natera, Inc. as a competitor in the transplant rejection monitoring space, particularly referencing Dr. Paul Billings' experience during the commercialization phase of Natera's blood test for kidney transplant rejection.
• The company estimates a $1 billion total addressable market for transplant rejection testing, indicating a significant market opportunity.
• The company aims to achieve non-inferiority to existing commercial rejection biomarkers, with expected results meeting or exceeding the sensitivity and specificity benchmarks observed in previous studies.

Management Changes

Stakeholder Impact

• Shareholders: Potential for long-term growth and value creation through transplant diagnostics.
• Employees: Opportunity to contribute to a transformative technology in transplant care.
• Customers (Transplant Centers): Access to faster, more affordable, and localized testing solutions.
• Patients: Improved access to transplant rejection monitoring and potentially better outcomes.

Next Steps

• Finalizing the clinical assay design based on feedback from research labs.
• Kicking off, conducting, and concluding the clinical trial for GraftAssureDx.
• Preparing for a second FDA pre-submission meeting to confirm endpoints.
• Signing up at least 20 transplant centers for the assay by the end of 2025.

Key Dates

Keywords

transplant, GraftAssure, VitaGraft, Oncocyte, diagnostics, rejection monitoring, clinical trial, FDA, Bio-Rad, dd-cfDNA, Medicare, IVD, oncology